Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial

The Lancet Oncology

Volumn 10, Issue 8, 2009, Pages 785-793

  Stupp, Roger ^a   Mayer, Michael ^f   Kann, Roger ^b   Weder, Walter ^c   Zouhair, Abderahim ^a   Betticher, Daniel C ^d   Roth, Arnaud D ^a   Stahel, Rolf A ^c   Majno, Sabine Balmer ^a   Peters, Solange ^a   Jost, Lorenz ^b   Furrer, Markus ^e   Thierstein, Sandra ^f   Schmid, Ralph A ^d   Hsu Schmitz, Shu Fang ^f   Mirimanoff, René Olivier ^a   Ris, Hans Beat ^a   Pless, Miklos ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^f SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL;

ADJUVANT THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ARTICLE; BRAIN INFARCTION; BRONCHOPLEURAL FISTULA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMPYEMA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEARING LOSS; HEMATOMA; HUMAN; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PERIOPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REOPERATION; RESPIRATORY FAILURE; TREATMENT OUTCOME; VOMITING; WOUND DEHISCENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PNEUMONECTOMY; RADIOTHERAPY; TAXOIDS;

EID: 67651146522     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70172-X     Document Type: Article

References (49)

1. Blackstock A.W., and Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 25 (2007) 4146-4152
2. Rigas J.R., and Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2 suppl 2 (2007) S77-S85
3. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
4. Dillman R.O., Herndon J., Seagren S.L., Eaton Jr. W.L., and Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
5. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 (2005) 5910-5917
6. Albain K.S., Crowley J.J., Turrisi III A.T., et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20 (2002) 3454-3460
7. Socinski M.A., Zhang C., Herndon II J.E., et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 15 (2004) 1033-1041
8. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83 (1991) 417-423
9. Sause W., Kolesar P., Taylor S.I., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
10. Roth J.A., Fossella F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 (1994) 673-680
11. Roth J.A., Atkinson E.N., Fossella F., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21 (1998) 1-6
12. Rosell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 (1994) 153-158
13. Garrido P., Gonzalez-Larriba J.L., Insa A., et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 25 (2007) 4736-4742
14. Martin L.W., Correa A.M., Hofstetter W., et al. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution. J Thorac Cardiovasc Surg 130 (2005) 1601-1610
15. Burdett S., Stewart L.A., and Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 1 (2006) 611-621
16. Betticher D.C., Schmitz S.H., Totsch M., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21 (2003) 1752-1759
17. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99 (2007) 442-450
18. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13 (1995) 1880-1892
19. Betticher D.C., Schmitz S.H., Totsch M., et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94 (2006) 1099-1106
20. Depierre A., Milleron B., Moro-Sibilot D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20 (2002) 247-253
21. Barlesi F., Doddoli C., Torre J.P., et al. Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy. Eur J Cardiothorac Surg 28 (2005) 629-634
22. Galetta D., Cesario A., Margaritora S., et al. Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach. Ann Thorac Surg 76 (2003) 1802-1808
23. Grunenwald D.H., Andre F., Le Pechoux C., et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 122 (2001) 796-802
24. Ichinose Y., Fukuyama Y., Asoh H., et al. Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer. Ann Thorac Surg 76 (2003) 1810-1814
25. Stamatis G., Eberhard W., and Pottgen C. Surgery after multimodality treatment for non-small-cell lung cancer. Lung Cancer 45 suppl 2 (2004) S107-S112
26. Pezzetta E., Stupp R., Zouhair A., et al. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg 27 (2005) 1092-1098
27. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
28. International Commission on Radiation Units and Measurements. ICRU Report No 50. Prescribing, recording, and reporting photon beam therapy (1993), ICRU Publications, Bethesda, MD
29. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
30. Ettinger D., and Johnson B. Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3 suppl 1 (2005) S17-S21
31. Jett J.R., Schild S.E., Keith R.L., and Kesler K.A. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edn). Chest 132 (2007) 266S-276S
32. Belani C.P., Wang W., Johnson D.H., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 (2005) 3760-3767
33. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
34. Jeremic B., Shibamoto Y., Acimovic L., and Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14 (1996) 1065-1070
35. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
36. Gandara D.R., Chansky K., Albain K.S., et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 8 (2006) 116-121
37. Gandara D.R., Chansky K., Albain K.S., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21 (2003) 2004-2010
38. DeCamp M.M., Rice T.W., Adelstein D.J., et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac Cardiovasc Surg 126 (2003) 17-27
39. Stamatis G., Eberhardt W., Stuben G., Bildat S., Dahler O., and Hillejan L. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 68 (1999) 1144-1149
40. Vokes E.E., Herndon II J.E., Kelley M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25 (2007) 1698-1704
41. Gottfried M., Ramlau R., Krzakowski M., et al. Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results. J Thorac Oncol 3 (2008) 152-157
42. Thomas M., Rube C., Hoffknecht P., et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9 (2008) 636-648
43. Weiden P.L., and Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG. Chest 106 (1994) 344S-347S
44. Martin J., Ginsberg R.J., Abolhoda A., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 72 (2001) 1149-1154
45. Pennathur A., Lindeman B., Ferson P., et al. Surgical resection is justified in non-small cell lung cancer patients with node negative T4 satellite lesions. Ann Thorac Surg 87 (2009) 893-899
46. Goldstraw P., Crowley J., Chansky K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2 (2007) 706-714
47. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (1985) 1604-1608
48. Chee K.G., Nguyen D.V., Brown M., Gandara D.R., Wun T., and Lara Jr. P.N. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med 168 (2008) 1541-1549
49. Albain K.S., Swann R.S., Rusch V.R., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). Proc Am Soc Clin Oncol 23 (2005) 7014